The Iliac/SFA/Popliteal Center

Filter Your Results

 

News

 

Long-Term Data From Liberty 360° Show Positive Impact for Patients Receiving Endovascular Therapy

With Ehrin J. Armstrong, MD; Jihad A. Mustapha, MD; George A. Pliagas, MD; and Jason A. Yoho, MD

September 2017—A roundtable discussion of the real-world LIBERTY 360° 12-month data and the study’s significance in treating patients with peripheral artery disease and critical limb ischemia.

The Stellarex Difference: Critical Components of an Optimal DCB

Manasi Ramachandran, PhD; and Michael S. Owens, PhD

September 2017—Since the first prototype of a paclitaxel drug-coated balloon (DCB) was developed, we have learned that DCB performance is built on a critical balance of multiple factors that…

The ILLUMENATE SFA Clinical Program

Henrik Schröder, MD; and Prakash Krishnan, MD

September 2017—Data on the Stellarex DCB for treatment of femoropopliteal arterial disease.

Surmodics' 0.014-Inch Low-Profile PTA Balloon Dilation Catheter Receives FDA Clearance and CE Mark Approval

September 18, 2017 -- Surmodics, Inc. announced that it has received US Food and Drug Administration 510(k) clearance and European CE Mark approval for its 0.014-inch low-prof…

Biotronik Studies Investigate Efficacy of Minimizing Metal Burden in SFA Therapy

September 18, 2017 -- Biotronik announced that data from various Biotronik studies demonstrating that reducing metal burden in superficial femoral artery (SFA) therapy could e…

MAJESTIC Data Shows Long-Term Freedom From Revascularization With Boston Scientific's Eluvia Stent System

September 18, 2017 -- Boston Scientific Corporation announced that the 3-year results from the MAJESTIC trial for the company's Eluvia paclitaxel-eluting vascular stent sy…

Efficacy Data Presented for iVascular’s Luminor DCB

September 18, 2017 -- iVascular SLU announced that the efficacy of the company's Luminor drug-coated balloon (DCB) in patients with peripheral arterial disease (PAD) was d…

Data From Early Feasibility PREVEIL Study Presented for Surmodics SurVeil DCB

September 13, 2017 -- Surmodics, Inc. announced that data from the PREVEIL early feasibility study of the company’s SurVeil drug-coated balloon (DCB) were reported by Ga…

 

advertisement

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.